RapamycinStudienlage & Dosis

Top-Studien zu Rapamycin

Sortiert nach einflussreichen Zitationen und Erscheinungsjahr.

1. 01

   Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis.

   Lancet·2007·n=18Meta-Analysis200 einflussreiche Zitationen

   <h4>Background</h4>Whether the two drug-eluting stents approved by the US Food and Drug Administration-a sirolimus-eluting stent and a paclitaxel-eluting stent-are associated with increased risks of death, myocardial infarction, or stent…

2. 02

   Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents.

   N Engl J Med·2007·n=495Meta-Analysis200 einflussreiche Zitationen

   <h4>Background</h4>The long-term effects of treatment with sirolimus-eluting stents, as compared with bare-metal stents, have not been established.<h4>Methods</h4>We performed an analysis of individual data on 4958 patients enrolled in 14…

3. 03

   Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.

   Current Biology·2004191 einflussreiche Zitationen

   The mammalian TOR (mTOR) pathway integrates nutrient- and growth factor-derived signals to regulate growth, the process whereby cells accumulate mass and increase in size. mTOR is a large protein kinase and the target of rapamycin, an…

4. 04

   Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control.

   Molecules and Cells·2002152 einflussreiche Zitationen

   The target of rapamycin (TOR) proteins in Saccharomyces cerevisiae, TOR1 and TOR2, redundantly regulate growth in a rapamycin-sensitive manner. TOR2 additionally regulates polarization of the actin cytoskeleton in a rapamycin-insensitive…

5. 05

   Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis.

   J Am Coll Cardiol·2015·n=52.158Meta-Analysis144 einflussreiche Zitationen

   <h4>Background</h4>Previous meta-analyses have investigated the relative safety and efficacy profiles of different types of drug-eluting stents (DES) and bare-metal stents (BMS); however, most prior trials in these meta-analyses reported…

   Befund: Late target-vessel revascularization was reduced with all drug-eluting stents compared with bare-metal stents.

6. 06

   Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.

   Molecules and Cells·2006131 einflussreiche Zitationen

   The drug rapamycin has important uses in oncology, cardiology, and transplantation medicine, but its clinically relevant molecular effects are not understood. When bound to FKBP12, rapamycin interacts with and inhibits the kinase activity…

7. 07

   A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents.

   Lancet·2004·n=5.103Meta-Analysis127 einflussreiche Zitationen

   <h4>Background</h4>Drug-eluting stents (DES) are associated with lower restenosis rates than bare-metal stents (BMS), but the benefits and safety of the new devices have not been systematically quantified across different trials. We…

8. 08

   Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies.

   Transplantation·2005·n=33.249Meta-Analysis125 einflussreiche Zitationen

   <h4>Background</h4>Immunosuppressive drug therapy has been identified as one etiological factor in the increased incidence of and deaths from malignancies in renal transplant recipients. In animal models, calcineurin inhibitors have a…

   Befund: In the Cox regression model, sirolimus/everolimus immunosuppression was linked to a reduced risk of any de novo cancer.

9. 09

   Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

   Nature Cell Biology·2004114 einflussreiche Zitationen

   The target of rapamycin (TOR) is a highly conserved protein kinase and a central controller of cell growth. In budding yeast, TOR is found in structurally and functionally distinct protein complexes: TORC1 and TORC2. A mammalian…

10. 10

    An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1*

    Journal of Biological Chemistry·2009104 einflussreiche Zitationen

    The mammalian target of rapamycin (mTOR) kinase is the catalytic subunit of two functionally distinct complexes, mTORC1 and mTORC2, that coordinately promote cell growth, proliferation, and survival. Rapamycin is a potent allosteric mTORC1…

Häufige Fragen

Verwandte Artikel